Journal ArticleDOI
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management
TLDR
Although the incidence of Candida infection was found to be increased by only a small degree during anti‐IL‐17 therapy, patients undergoing such treatment should be monitored for fungal infection and treated as necessary.Abstract:
The recognition of the central role of interleukin (IL)-17A in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes. IL-17A also plays an important role in immunological protection against infections, especially those due to Candida spp., as evidenced by findings in patients with genetic defects in IL-17-related immune responses. To assess the potential of anti-IL-17 treatment to promote Candida infections, here we have systematically reviewed published clinical trials of patients with psoriasis or psoriatic arthritis. Candida infections were reported in 4·0% of patients treated with brodalumab, 1·7% with secukinumab and 3·3% with ixekizumab vs. 0·3%, 2·3% and 0·8% of those assigned to placebo, ustekinumab or etanercept, respectively. Although the incidence of Candida infection was found to be increased by only a small degree during anti-IL-17 therapy, patients undergoing such treatment should be monitored for fungal infection and treated as necessary. We propose adoption of the recently updated recommendations for the practical management of Candida infection in patients administered IL-17 inhibitors.read more
Citations
More filters
Journal ArticleDOI
IL-17 Signaling: The Yin and the Yang
TL;DR: This review discusses both the activators and the inhibitors of IL-17 signal transduction, and also the physiological implications of these events, and highlights the surprisingly diverse means by which these regulators control expression ofIL-17-dependent inflammatory genes, as well as the major target cells that respond to IL- 17 signaling.
Journal ArticleDOI
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich,Kim A. Papp,Andrew Blauvelt,Stephen K. Tyring,Rodney Sinclair,Diamant Thaçi,Kristine Nograles,Anish Mehta,Nicole Cichanowitz,Qing Li,Kenneth Liu,Carmen La Rosa,Stuart A. Green,Alexa B. Kimball +13 more
TL;DR: Whether tildrakizumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis is investigated in two phase 3 trials and the proportion of patients achieving PASI 75 and PGA response at week 12 is examined.
Journal ArticleDOI
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases
Kübra Bunte,Thomas Beikler +1 more
TL;DR: A review of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the pathogenesis of IMIDs aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL
Journal ArticleDOI
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Kevin L. Winthrop,Xavier Mariette,José Tiago Silva,Esther Benamu,Leonard H. Calabrese,Alexandre Dumusc,Josef S Smolen,José María Aguado,Mario Fernández-Ruiz,Mario Fernández-Ruiz +9 more
TL;DR: The safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations are reviewed, from an Infectious Diseases perspective.
Journal ArticleDOI
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP
Hideki Fujita,Tadashi Terui,Koremasa Hayama,Masashi Akiyama,Shigaku Ikeda,Tomotaka Mabuchi,Akira Ozawa,Takuro Kanekura,Michiko Kurosawa,Mayumi Komine,Kimiko Nakajima,Shigetoshi Sano,Osamu Nemoto,Masahiko Muto,Yasutomo Imai,Kiyofumi Yamanishi,Yumi Aoyama,Keiji Iwatsuki +17 more
TL;DR: Since there are few clinical trial data with high levels of evidence for this rare disease, recommendations by the committee are described in the present guidelines.
References
More filters
Journal ArticleDOI
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas,Carol A. Kauffman,David R. Andes,Cornelius J. Clancy,Kieren A. Marr,Luis Ostrosky-Zeichner,Annette C. Reboli,Mindy G. Schuster,Jose A. Vazquez,Thomas J. Walsh,Theoklis E. Zaoutis,Jack D. Sobel +11 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Journal ArticleDOI
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
TL;DR: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Journal ArticleDOI
Structure and signalling in the IL-17 receptor family.
TL;DR: Research defining the signal transduction pathways induced by IL-17R family cytokines has lagged behind that of other cytokine families, but studies in the past 2 years have begun to delineate unusual functional motifs and new proximal signalling mediators used by the IL- 17R family to mediate downstream events.
Journal ArticleDOI
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas,Carol A. Kauffman,David R. Andes,Cornelius J. Clancy,Kieren A. Marr,Luis Ostrosky-Zeichner,Annette C. Reboli,Mindy G. Schuster,Jose A. Vazquez,Thomas J. Walsh,Theoklis E. Zaoutis,Jack D. Sobel +11 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Journal ArticleDOI
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Kim A. Papp,Craig L. Leonardi,Alan Menter,Jean-Paul Ortonne,James G. Krueger,Gregory Kricorian,Girish A. Aras,Juan Li,Chris B. Russell,Elizabeth H.Z. Thompson,Scott Baumgartner +10 more
TL;DR: Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.
Related Papers (5)
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber,Bruce E. Sands,Steve Lewitzky,Marc Vandemeulebroecke,Walter Reinisch,Peter D.R. Higgins,Jan Wehkamp,Brian G. Feagan,Michael D Yao,Marek Karczewski,Jacek Karczewski,Nicole Pezous,Stephan Bek,Gerard Bruin,Bjoern Mellgard,Claudia Berger,Marco Londei,Arthur P. Bertolino,Gervais Tougas,Simon Travis +19 more
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel,Sophie Cypowyj,Jacinta Bustamante,Jill F. Wright,Luyan Liu,Hye Kyung Lim,Mélanie Migaud,Laura Israel,Maya Chrabieh,Magali Audry,Matthew Gumbleton,Antoine Toulon,Christine Bodemer,Jamila El-Baghdadi,Matthew J. Whitters,Theresa Paradis,Jonathan Brooks,Mary Collins,Neil M. Wolfman,Saleh Al-Muhsen,Miguel Galicchio,Laurent Abel,Laurent Abel,Capucine Picard,Jean-Laurent Casanova +24 more
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl,Bruce Strober,Alan Menter,Kenneth B. Gordon,Jolanta Weglowska,Lluís Puig,Kim A. Papp,Lynda Spelman,Darryl Toth,Francisco A. Kerdel,April W. Armstrong,Georg Stingl,Alexa B. Kimball,Hervé Bachelez,Jashin J. Wu,Jeffrey J. Crowley,Richard G. Langley,Tomasz Blicharski,Carle Paul,Jean-Philippe Lacour,Stephen K. Tyring,Leon H Kircik,Sergio Chimenti,Kristina Callis Duffin,Jerry Bagel,John Koo,Gary Aras,Joanne Li,Wenjie Song,Cassandra E Milmont,Yifei Shi,Ngozi Erondu,Paul Klekotka,Brian L Kotzin,Ajay Nirula +34 more
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I
Anne Puel,Anne Puel,Rainer Doffinger,Angels Natividad,Angels Natividad,Maya Chrabieh,Maya Chrabieh,Gabriela Barcenas-Morales,Capucine Picard,Capucine Picard,Aurélie Cobat,Aurélie Cobat,Marie Ouachée-Chardin,Antoine Toulon,Jacinta Bustamante,Jacinta Bustamante,Saleh Al-Muhsen,Mohammed Al-Owain,Peter D. Arkwright,Colm Costigan,Vivienne McConnell,Andrew J. Cant,Mario Abinun,Michel Polak,Michel Polak,Pierre Bougnères,Dinakantha S. Kumararatne,László Maródi,Amit Nahum,Chaim M. Roifman,Stéphane Blanche,Alain Fischer,Alain Fischer,Christine Bodemer,Laurent Abel,Laurent Abel,Laurent Abel,Desa Lilic,Jean-Laurent Casanova +38 more